Burning Rock Biotech Limited

28.97-1.32-4.36%Vol 551.73K1Y Perf 19.16%
Apr 9th, 2021 16:00 DELAYED
BID28.81 ASK30.65
Open30.90 Previous Close30.29
Pre-Market- After-Market-
 - -  - -%
Target Price
38.35 
Analyst Rating
— — 0.00
Potential %
32.38 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     52.97
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     49.93
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap3.01B 
Earnings Rating
Price Range Ratio 52W %
48.93 
Earnings Date
11th Mar 2021

Today's Price Range

28.8230.90

52W Range

18.6439.75

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Strong Buy
Performance
1 Week
-1.06%
1 Month
-10.14%
3 Months
16.49%
6 Months
9.32%
1 Year
19.16%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BNR28.97-1.3200-4.36
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.16-0.23-43.75
Q03 2020-0.11-0.18-63.64
Q02 2020-0.20-0.38-90.00
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.16
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume551.73K
Shares Outstanding103.81M
Trades Count1.98K
Dollar Volume10.00M
Avg. Volume389.53K
Avg. Weekly Volume393.68K
Avg. Monthly Volume341.81K
Avg. Quarterly Volume407.68K

Burning Rock Biotech Limited (NASDAQ: BNR) stock closed at 28.97 per share at the end of the most recent trading day (a -4.36% change compared to the prior day closing price) with a volume of 551.74K shares and market capitalization of 3.01B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 753 people. Burning Rock Biotech Limited CEO is Yusheng Han.

The one-year performance of Burning Rock Biotech Limited stock is 19.16%, while year-to-date (YTD) performance is 25.41%. BNR stock has a five-year performance of %. Its 52-week range is between 18.64 and 39.75, which gives BNR stock a 52-week price range ratio of 48.93%

Burning Rock Biotech Limited currently has a PE ratio of -25.80, a price-to-book (PB) ratio of 7.64, a price-to-sale (PS) ratio of 45.36, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -31.33%, a ROC of -11.04% and a ROE of -50.89%. The company’s profit margin is -97.54%, its EBITDA margin is -91.40%, and its revenue ttm is $56.30 Million , which makes it $0.65 revenue per share.

Of the last four earnings reports from Burning Rock Biotech Limited, there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.16 for the next earnings report. Burning Rock Biotech Limited’s next earnings report date is -.

The consensus rating of Wall Street analysts for Burning Rock Biotech Limited is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Burning Rock Biotech Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Burning Rock Biotech Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Burning Rock Biotech Limited has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.46, ATR14 : 2.54, CCI20 : -47.96, Chaikin Money Flow : -0.11, MACD : 0.92, Money Flow Index : 25.76, ROC : -16.47, RSI : 47.50, STOCH (14,3) : 28.75, STOCH RSI : 0.00, UO : 42.05, Williams %R : -71.25), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Burning Rock Biotech Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and LungPlasma. The company has developed various cancer detection products , involving tumor targeting, oncomitant diagnosis of immune drugs, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress and detection of tumor sensitivity.

CEO: Yusheng Han

Telephone: +86 2034037871

Address: No. 7, Luoxuan 4th Road, Guangzhou 510005, , CN

Number of employees: 753

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

55%45%

Bearish Bullish

70%30%

News

Stocktwits